Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Comparative Growth Hormone Fragment Studies : Comparing AOD 9604 with full-length human growth hormone and other growth hormone fragments to find out which parts of the hormone are responsible for specific metabolic effects
Follicles that would have miniaturized maintain their productive capacity
& Oben, J
Here are some key points to consider: Variable Results: The effectiveness of B12 and Lipo injections can differ significantly from one person to another
Retrieved from Halford, J.C
AOD-9604 FDA Approval History At a glance FDA approval status / Never approved for any indication in the United States NDA filing history / No New Drug Application has ever been submitted to FDA Chemical identity / Synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with a tyrosine residue added at the C-terminus Developer / Metabolic Pharmaceuticals Ltd (Melbourne, Australia), now defunct Clinical trial outcome / Phase IIb trial (2007) failed to meet primary efficacy endpoint for obesity FDA compounding status / Placed on Category 2 list
US$ 26.30
US$ 24.21
US$ 26.29
US$ 28.88
US$ 27.59
US$ 27.58
US$ 29.92
